Across TCGA pan-cancer cohorts, HSH2D mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated HSH2D data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher HSH2D mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated HSH2D expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC, LUAD, and LSCC are the cancer types where HSH2D mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	All	0.686	0.293	.004	9	view →
LUAD	DFS	Quartile	III,IV	0.254	0.856	.024	7	view →
LSCC	DFS	Tertile	II,III,IV	0.471	0.793	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: HSH2D tumor-vs-normal RNA expression · all HSH2D data types